On the other hand, aldose reductase (AR, AKR1B1) emerged as a novel candidate for SA-AKI treatment, showcasing the potential of proteomics in uncovering unexplored therapeutic targets. The gene discussed is AKR1B1; the disease is acute kidney injury.